Artículos por temáticas

Astrocyte molecular signatures in Huntington's disease.

Diaz-Castro B, Gangwani MR, Yu X, Coppola G, Khakh BS.

Sci Transl Med. 2019 Oct 16;11(514). pii: eaaw8546. doi: 10.1126/scitranslmed.aaw8546.

The caudate nucleus undergoes dramatic and unique transcriptional changes in human prodromal Huntington's disease brain.

Agus F, Crespo D, Myers RH, Labadorf A.

BMC Med Genomics. 2019 Oct 16;12(1):137. doi: 10.1186/s12920-019-0581-9.

A Combinatorial Cell and Drug Delivery Strategy for Huntington's Disease Using Pharmacologically Active Microcarriers and RNAi Neuronally-Committed Mesenchymal Stromal Cells.

André EM, Delcroix GJ, Kandalam S, Sindji L, Montero-Menei CN.

Pharmaceutics. 2019 Oct 12;11(10). pii: E526. doi: 10.3390/pharmaceutics11100526.

Loss of huntingtin function slows synaptic vesicle endocytosis in striatal neurons from the htt(Q140/Q140) mouse model of Huntington's disease.

McAdam RL, Morton A, Gordon SL, Alterman JF, Khvorova A, Cousin MA, Smillie KJ.

Neurobiol Dis. 2019 Oct 12;134:104637. doi: 10.1016/j.nbd.2019.104637. [Epub ahead of print]

Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington's disease: a review of clinical trial data.

Claassen DO, Philbin M, Carroll B.

Expert Opin Pharmacother. 2019 Oct 15:1-13. doi: 10.1080/14656566.2019.1674281. [Epub ahead of print]

Psychosis and longitudinal outcomes in Huntington disease: the COHORT Study.

Connors MH, Teixeira-Pinto A, Loy CT.

J Neurol Neurosurg Psychiatry. 2019 Oct 13. pii: jnnp-2019-320646. doi: 10.1136/jnnp-2019-320646. [Epub ahead of print]

How different aspects of motor dysfunction influence day-to-day function in huntington's disease.

Carlozzi NE, Schilling SG, Boileau NR, Chou KL, Perlmutter JS, Frank S, McCormack MK, Stout JC, Paulsen JS, Lai JS, Dayalu P.

Mov Disord. 2019 Oct 14. doi: 10.1002/mds.27866. [Epub ahead of print]

A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes.

Ciosi M, Maxwell A, Cumming SA, Hensman Moss DJ, Alshammari AM, Flower MD, Durr A, Leavitt BR, Roos RAC; TRACK-HD team.; Enroll-HD team., Holmans P, Jones L, Langbehn DR, Kwak S, Tabrizi SJ, Monckton

EBioMedicine. 2019 Oct 4. pii: S2352-3964(19)30624-3. doi: 10.1016/j.ebiom.2019.09.020. [Epub ahead of print]

Acute manganese treatment restores defective autophagic cargo loading in Huntington's Disease cell lines.

Bryan MR, O'Brien MT, Nordham KD, Rose DIR, Foshage AM, Joshi P, Nitin R, Uhouse MA, Di Pardo A, Zhang Z, Maglione V, Aschner M, Bowman AB.

Hum Mol Genet. 2019 Oct 10. pii: ddz209. doi: 10.1093/hmg/ddz209. [Epub ahead of print]

Expanded polyglutamine impairs normal nuclear distribution of fused in sarcoma and poly (rC)-binding protein 1 in Huntington's disease.

Mori S, Honda H, Ishii T, Yoshimura M, Sasagasako N, Suzuki SO, Taniwaki T, Iwaki T.

Neuropathology. 2019 Oct;39(5):358-367. doi: 10.1111/neup.12600. Epub 2019 Oct 9.

Clinical and Genetic Profiles in Chinese Patients with Huntington's Disease: A Ten-year Multicenter Study in China.

Li HL, Li XY, Dong Y, Zhang YB, Cheng HR, Gan SR, Liu ZJ, Ni W, Burgunder JM, Yang XW, Wu ZY.

Aging Dis. 2019 Oct 1;10(5):1003-1011. doi: 10.14336/AD.2018.0911. eCollection 2019 Oct.

An exploration of physical activity experiences throughout the Huntington's disease journey: supporting development of theoretically underpinned complex interventions

Hamana K, Quinn L, Gambling T, Busse M.

Disabil Rehabil. 2021 Jun;43(11):1565-1575. doi: 10.1080/09638288.2019.1671501. Epub 2019 Oct 7.

Prolyl oligopeptidase inhibition reduces PolyQ aggregation and improves cell viability in cellular model of Huntington's disease.

Norrbacka S, Lindholm D, Myöhänen TT.

J Cell Mol Med. 2019 Sep 29. doi: 10.1111/jcmm.14675. [Epub ahead of print] No abstract available.

What is gained or 'lost in translation' in Huntington's disease.

Brouillet E, Merienne K.

Brain. 2019 Oct 1;142(10):2900-2902. doi: 10.1093/brain/awz274. No abstract available.

Antisense oligonucleotides might change the therapeutic landscape for Huntington's disease.

Paulsen JS, Coffey CS.

Lancet Neurol. 2019 Oct;18(10):911-912. doi: 10.1016/S1474-4422(19)30329-1. No abstract available.